Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?
|
|
- Magdalen Cain
- 5 years ago
- Views:
Transcription
1 New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH MSc. FRCP(C) Associate Professor National Jewish Health University of Colorado School of Medicine Advisory Boards Astra Zeneca Genentech Glaxo Smith Kline Sanofi Sunovion Research Grants by Pharmaceutical Companies None Changing Epidemiology: Quick Facts During the year million emergency department visits 8 million physician office and hospital outpatient visits The Majority of Healthcare Costs for Managing COPD Are Associated With Exacerbations Total costs for COPD were estimated to be $49.9 billion in $29.5 billion in direct costs Over.75 million hospitalizations 119,000 deaths 50%-75% of direct costs for COPD are for services associated with exacerbations 2 Despite its ease of diagnosis, COPD remains an underdiagnosed disease, chiefly in its milder and more treatable form. Centers for Disease Control and Prevention Mannino et al. COPD disease surveillance United States, MMWR. 2002;51(SS 6): National Institutes of Health, National Heart, Lung & Blood Institute. Morbidity and Mortality: 2009 chart book on cardiovascular, lung and blood diseases. Accessed January 18, American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of patients 4 with COPD. Updated Version Accessed January 18,
2 Current GOLD Paradigm for COPD Precision Medicine in United Airway Disease: A treatable traits approach. Yii et al;allergy. 2018;00:1 15 Endotype and Phenotype Phenotype Definition: Current and proposed COPD Phenotypes An observable characteristic or trait of a disease without any implication of a mechanism. Prospective validation of COPD phenotypes against clinical outcomes or response to treatment is essential in defining a phenotype Accepted Phenotypes 1. Alpha 1 AT Deficiency 2. Emphysema/hyperinflation 3. Frequent Exacerbator Proposed Phenotypes 1. Non smokers 2. Rapid decliners 3. Asthma/COPD overlap 4. Eosinophilic 5. Mild airflow obstruction/severe dyspnea 6. Chronic bronchitis 7. GERD comorbidity 8. Cardiovascular co morbidity 9. OSA comorbidity 10. CT Phenotypes 2
3 Phenotype Clusters and Networks Many overlaps and connections are endless OSA comorbidity Pulmonary hypertension CT Phenotypes Alpha 1 AT Deficiency Lung Cancer Non smokers Eosinophilic Asthma/COPD overlap Chronic bronchitis Frequent Exacerbator Rapid decliners Microbiome changes GERD comorbidity Phenotype Treatable Traits Emphysema/ hyperinflation Mild airflow obstruction/ severe dyspnea Cardiovascular co morbidity Obesity Comorbidity Endotypes Smoking Status Endotype Definition Endotype: Subtype of a condition, defined by a distinct functional or pathobiological mechanism. It is envisaged that patients with a specific endotype present themselves within phenotypic clusters of diseases. Precision Medicine: Treatable Traits Precision medicine is defined as treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical patients Agusti, et al. ERJ 2016;47:
4 Biologics? Non pharmacological COPD Treatment Options Smoking cessation Education, self management Cardiopulmonary rehabilitation Pneumococcal and influenza vaccination Long term oxygen therapy Long term non invasive ventilation for history of hopitalization for acute respiratory failure Bronchoscopic or surgical lung volume reduction Airway Clearance for significant bronchorrhea Stepwise management pharmacotherapy UPDATED 2017 Diagnosis Symptom control & risk factors (including lung function) Inhaler technique & adherence Patient preference BIOLOGICS IN ASTHMA Symptoms Exacerbations Side-effects Patient satisfaction Lung function Asthma medications Non-pharmacological strategies Treat modifiable risk factors STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE Other controller options RELIEVER STEP 1 STEP 2 Low dose ICS Consider low Leukotriene receptor antagonists (LTRA) dose ICS Low dose theophylline* As-needed short-acting beta2-agonist (SABA) STEP 3 Refer for *Not for children <12 years add-on **For children 6-11 years, the treatment preferred Step 3 treatment is e.g. Med/high tiotropium,* medium dose ICS ICS/LABA anti-ige, # Low dose anti-il5* For patients prescribed BDP/formoterol or BUD/ ICS/LABA** formoterol maintenance and reliever therapy Med/high dose ICS Add tiotropium* Add low Low dose ICS+LTRA High dose ICS dose OCS Tiotropium by mist inhaler is (or + theoph*) + LTRA an add-on treatment for (or + theoph*) patients 12 years with a As-needed SABA or history of exacerbations low dose ICS/formoterol # GINA 2017, Box 3-5 (2/8) (upper part) 4
5 Biologics and chronic obstructive pulmonary disease: Pavord et al JACI 2018: 141; Biologic Drugs: A new Target Therapy in COPD Yousef A et al JCOPD:2018;15(2) T2 high COPD vs Non T2 COPD Benralizumab for COPD and Sputum Eosinophilia: a randomized, double blind, placebo controlled, phase 2a study Brightling et al Lancet Respir. Med 2014;2: BIOLOGICS IN TH 2 high COPD 101 patients At least 1 exacerbation in previous year Eosinophils > 3% in sputum Benralizumab 100 mg SQ vs placebo Did not meet primary outcome in reducing exacerbations with eosinophilic COPD Post hoc analysis suggested efficacy in FEV 1 and exacerbations for Blood eos > 250 cells/μl or sputum eos > 2%. 5
6 Benralizumab for COPD and Sputum Eosinophilia: a randomized, double blind, placebo controlled, phase 2a study Brightling et al Lancet Respir. Med 2014;2: Benralizumab for COPD and Sputum Eosinophilia: a randomized, double blind, placebo controlled, phase 2a study Brightling et al Lancet Respir. Med 2014;2: Benralizumab for COPD and Sputum Eosinophilia: a randomized, double blind, placebo controlled, phase 2a study Brightling et al Lancet Respir. Med 2014;2: Change in Eosinophils over time Benralizumab for COPD and Sputum Eosinophilia: a randomized, double blind, placebo controlled, phase 2a study Brightling et al Lancet Respir. Med 2014;2: Adverse Events at least 5% and more common than in placebo group Placebo (n=50) Benralizumab (n=51) TEAE Serious TEAE TEAE leading to D/C 2 (4%) 3 (65) Injection site reactions 4(8%) 13(25%) infections 10 (20%) 16 (31%) Skin reactions 6(12%) 10(20%) Cardiac disorders 2 (4%) 7(14%) Renal Disorders 2(4%) 3(6%) 6
7 Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease Phase 3 DBRCT parallel group Metrex conducted in 16 countries Mepolizumab 100 mg or placebo Triple inhaler therapy Q 4 week injection X 52 weeks + 8 wk. follow up Metreo in 15 countries Mepolizumab 100, Mepolizumab 300, Placebo Triple inhaler therapy Q 4 week injection x 52 weeks + 8 wk. Follow up Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease Population: > 40 years old on triple therapy at least ICS+/ LABA, +/ LAMA, +/ PDE4 +/ methylxanthine X 12 months On LABA/ICS/LAMA for at least 3 months prior to entry Diagnosed with COPD > 1 year FEV 1 /FVC < 0.70 PBD FEV % predicted 2 or more moderate exacerbations or at least 1 severe exacerbation (hospitalization) in previous 12 months Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease Primary Endpoint: Annual Rate of exacerbations (moderate or severe) Secondary endpoints Time to first moderate or severe exacerbation Annual rate of exacerbations leading to ER or hospitalization or both Change in COPD Assessment Test Score Change St. George Respiratory Questionnaire Score 7
8 Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease Metrix Study Modified Intention to treat with an Eosinophilic phenotype Metreo Study Modified Intention to treat population Oral corticosteroids with or without antibiotics Antibiotics alone Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease Exacerbation Rate Ratio According to Eosinophil Count 8
9 Biologics and chronic obstructive pulmonary disease: Pavord et al JACI 2018: 141; BIOLOGIC TARGETS FOR NON T2 COPD CXCR 2 Receptor Antagonist MK7123: Phase 2 Proof of Concept Trial for COPD Rennard et al AJRCCM 191: CXCR 2 Receptor Antagonist MK7123: Phase 2 Proof of Concept Trial for COPD Rennard et al AJRCCM 191: CXCR 2 Receptor Antagonist MK7123: Phase 2 Proof of Concept Trial for COPD Rennard et al AJRCCM 191: Change in FEV1 over 26 weeks 9
10 CXCR 2 Receptor Antagonist MK7123: Phase 2 Proof of Concept Trial for COPD Rennard et al AJRCCM 191: Small improvement in FEV 1 in 50 mg dose group only 160 cc improvement versus placebo in current smokers only Study terminated early at 12 months due to subject attrition Higher rate of infection in treatment arms than placebo for those staying in trial > 6 months Further research not progressing Other Anti Neutrophilic (Non T2) Candidate Biologics Cytokine Population Study Sample size IL 8 Mod severe IL 8 mab 800 mg loading dose then 400 mg/month x 2 months 1 Clinical Outcomes 109 +ve TDI score. ve for PFT, 6MW, rescue Albuterol 234 Negative: CRQ TNFα Mod severe Anti TNFα 3 mg/kg or 5 mg/kg x 44 weeks 2 PFT QOL Exacerbations IL 1β IL 1α IL 6 IL 17 Moderate to very severe No studies to date No studies to date AntiIL1R ve Mod severe exacerbations ve SGRQ 1. Mahler et al. Chest.2004;126(3): Rennard et al. AJRCCM 2007, may;175(9): Calverley et al. Respir Res 2017;18(1):153 No benefit in Asthma trials Secondary outcomes and Adverse Events Increased cancer risks Increased infections Neutrophilic (Non T2) Candidate Biologics Considerations Clinical safety of neutrophil reduction is uncertain Neutrophil subtypes have different functions CXCR 2 and macrolides both reduce neutrophils CXCR 2 reduces exacerbations better in smokers Macrolides reduce exacerbations better in exsmokers Suggests 2 different types of neutrophilic inflammation in COPD Current Smoker Neutrophil Endotypes? Ex Smoker Microbiome Adapted from Pavord,I. et al JACI 2018: 141;
11 Non Biologic Alternatives for Neutrophil Inflammation Macrolide Antibiotics PDE4 inhibitors (Roflumilast) PDE3/PDE4 combination Macrolides Antimicrobial Anti inflammatory Augment Macrophage function Enhance Steroid efficacy Azithromycin: Mechanisms of action and their relevance for clinical applications. Parnham et al Pharmacology&Therapeutics 143(2014) Azithromycin for Prevention of Exacerbations of COPD Albert et al NEJM 2011 Aug 25;365(8): DESIGN: azithromycin, 250 mg daily (570 participants) vs placebo (572 participants) 1 year in addition to their usual care. follow up: 89% in the azithromycin group; 90% in the placebo group. RESULTS: The median time to the first exacerbation was Azithromycin: 266 days (95% confidence interval [CI], 227 to 313) azithromycin Placebo: 174 days (95% CI, 143 to 215) (P<0.001). The frequency of exacerbations: exacerbations per patient year Azithromycin: 1.48 vs Placebo: 1.83 (P=0.01) Hazard ratio for having an acute exacerbation of COPD per patient year azithromycin group was 0.73 (95% CI, 0.63 to 0.84; P<0.001). 11
12 Azithromycin for Prevention of Exacerbations of COPD Albert et al NEJM 2011 Aug 25;365(8): Azithromycin Placebo Azithromycin for Prevention of Exacerbations of COPD Albert et al NEJM 2011 Aug 25;365(8): Secondary Outcomes St. George's Respiratory Questionnaire: % subjects with > MCID of 4 units. 43% in the azithromycin group 36% in the placebo group (P=0.03). Proportion free of COPD Exacerbations p= by log rank test and Wilcoxon signed rank test ADVERSE EVENTS: 1. Hearing decrements: azithromycin group vs placebo group (25% vs. 20%, P=0.04). 2. Azithromycin Resistance Not detected in this study but inconclusive Follow up (days) Effect of Roflumilast and Inhaled Corticosteroid/Long ActingB2 Agonists on Chronic Obstructive Lung Disease Exacerbations )RE 2 SPOND Martinez, et al. AJRCCM 2016;194(5): 559. Effect of Roflumilast and Inhaled Corticosteroid/Long ActingB2 Agonists on Chronic Obstructive Lung Disease Exacerbations )RE 2 SPOND Martinez, et al. AJRCCM 2016;194(5): 559. (n=1,178) (n=1,174) 0.61 (0.39,0.95)* p = (0.77,1.27)* P=0.921 * Rate Ratio (95% CI) 0.96(0.83,1.11)* P= Martinez, et al. AJRCCM 2016;194(5):
13 PDE3/PDE4 Inhibitor Inhaled agent PDE3 smooth muscle relaxant PDE4 anti inflammatory with effects on neutrophils The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD Singh et al ERJ Aug 2018 (Early view) Two Phase 2 4 week multicenter trial dose ranging 6 way cross over study Dose range (0.75 mg, 1.5 mg, 3 mg, or 6 mg) Compared to: 1. Study 1: Salbutamol 200 µg and Ipratropium Bromide 40 µg 2. Study 2: Tiotropium (18 µg) The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD Singh et al ERJ Aug 2018 (Early view) The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD Singh et al ERJ Aug 2018 (Early view) Study 1 13
14 The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD Singh et al ERJ Aug 2018 (Early view) The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD Singh et al ERJ Aug 2018 (Early view) This study did not look at exacerbations Future studies will examine this important component of this combination therapy. Clusters and Networks Phenotype, Endotype or Treatable Traits? Precision medicine in united airway disease: A treatable traits approach. Yii et al;allergy. 2018;00:1 15 OSA comorbidity Lung Cancer Chronic bronchitis Rapid decliners Pulmonary hypertension CT Phenotypes Eosinophilic Asthma/COPD overlap Frequent Exacerbator Microbiome changes Alpha 1 AT Deficiency Non smokers GERD comorbidity Emphysema/ hyperinflation Mild airflow obstruction/ severe dyspnea Cardiovascular co morbidity Obesity Smoking Status Precision medicine in united airways disease: A treatable traits approach, First published: 05 June 2018, DOI: ( /all.13496) 14
15 COPD Assessment Control Panel Lange P. et al Int.J.COPD (First World lung disease Summit 2016:11;3 12) New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? SUMMARY COPD patients are a heterogeneous population with a wide array of variable characteristics that can impact response to treatment Phenotypes lack precision to find one intervention that will address all components of their COPD Identifying treatable traits is the most practical approach Identifying endotypes will allow for greater precision in treatment Managing co morbidities is often as important as managing their COPD 15
Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationCOPD: From Phenotypes to Endotypes. MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI
COPD: From Phenotypes to Endotypes MeiLan K Han, M.D., M.S. Associate Professor of Medicine University of Michigan, Ann Arbor, MI Presenter Disclosures MeiLan K. Han Consulting Research support Novartis
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2015?
Global Initiative for Asthma (GINA) What s new in GINA 2015? GINA Global Strategy for Asthma Management and Prevention What s new in GINA 2015 (1) Add-on tiotropium by soft-mist inhaler is a new other
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationThe Journal Club: COPD Exacerbations
252 The Journal Club: COPD Exacerbations Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club The Journal Club: COPD Exacerbations Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationCHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA
CHRONIC OBSTRUCTIVE LUNG DISEASE (COPD), BRONCHIAL ASTHMA GOLD GINA Chronic Obstructive Pulmonary Disease (COPD) COPD is currently the fourth leading cause of death in the world.1 COPD is projected to
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationNew TLD Indication: Asthma RELIEF-1 Study. Nick ten Hacken, MD Study Co-Principal Investigator
New TLD Indication: Asthma RELIEF-1 Study Nick ten Hacken, MD Study Co-Principal Investigator The Burden of Asthma WW Adult Asthma Prevalence 230.5 Million Mild/Intermittent 161.9 Million (70%) Moderate
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationGoals and Learning Objectives
Small Airways (SAW) Symposium: Asthma Treatment Issues. New Bronchodilator for Asthma: A Patient Centric Approach for Treating Asthma Stephen P. Peters, MD, PhD, FAAAAI, FACP, FCCP, FCPP Thomas H. Davis
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationTraiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
More informationDr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective
Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland
More information11/27/18. Challenges in Pulmonary and Critical Care: COPD So Much is New! Faculty. Disclosures
Challenges in Pulmonary and Critical Care: 2018 COPD So Much is New! 1 Faculty Anas Hadeh, MD, FCCP Director, Pulmonary and Critical Care Medicine Fellowship Program Affiliate Assistant Professor of Clinical
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationWho can get most benefit
Who can get most benefit from tiotropium in asthma? Y-M. Oh Asan Medical Center Univ. of Ulsan College of Medicine Seoul, Korea Tiotripium for Asthma 1 New in GINA 2015 Add-on tiotropium by soft-mist inhaler
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationChronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
10:50-11:50am Case Studies in Pulmonary Medicine for the Primary Care Clinician SPEAKERS Timothy J. Scialla, MD Common Shortcuts/Common Misperceptions Smoking + Dyspnea = COPD Hospitalization for cough
More informationA Study of Prescription Pattern in the Management of COPD in a Tertiary Care Hospital.
DOI: 10.21276/aimdr.2016.2.3.39 Original Article ISSN (O):2395-2822; ISSN (P):2395-2814 A Study of Prescription Pattern in the Management of COPD in a Tertiary Care Hospital. Mazher Maqusood 1, Farhan
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationPulmonary and Critical Care Year in Review
Pulmonary and Critical Care Year in Review Heath E Latham, MD Assistant Professor University of Kansas Dept of Internal Medicine Division of Pulmonary and Critical Care None Disclosure Lung Cancer Screening
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationERS Investor & Analyst Event. Munich Tuesday 9 th September 2014
ERS Investor & Analyst Event Munich Tuesday 9 th September 2014 Darrell Baker SVP, Global Head of Respiratory Agenda GSK s Respiratory Portfolio Eosinophils Research in COPD Eosinophils Clinical Experience
More informationSevere Asthma & Exacerbations: Dawn of a New Era?
Severe Asthma & Exacerbations: Dawn of a New Era? Christophe von Garnier Department of Pulmonary Medicine Syndromes, Phenotypes & Endotypes Asthma Syndrome Variable symptoms, expiratory airflow limitation,
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationCOPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK
COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK Presenter Disclosures Wisia Wedzicha All disclosures prior
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationAsthma and COPD. Health Net Provider Educational Webinar
Asthma and COPD Health Net Provider Educational Webinar AstraZeneca 2015 Disclosures Presenters today are employed by Astra Zeneca and have nothing to disclose. This presentation is free from bias. 2 Objectives
More informationUpdate on Pulmonary Diseases. Jeffrey Lessar, MD
Update on Pulmonary Diseases Jeffrey Lessar, MD 1 No disclosures to make No conflicts 2 Goals Update on key changes in Pulmonary Therapy 3 Spirometry Spirometry FEV1- forced expiratory Volume in 1 Sec
More informationAirway Vista Background
Airway Vista 2013 Chronic Obstructive Airway Diseases Symposium Asan Medical Center, Seoul, South Korea When Should Macrolide Antibiotics be Prescribed to Prevent COPD Exacerbations in Usual Clinical Practice?
More informationJournal of the COPD Foundation. Journal Club. Chronic Obstructive Pulmonary Diseases:
85 Journal Club Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations: inhaled corticosteroid, ICS; long acting β 2 -agonist,
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationTreatment of Severe Asthma: Biologics to Bronchial Thermoplasty. Disclosures
Treatment of Severe Asthma: Biologics to Bronchial Thermoplasty Monica Kraft, M.D. Robert and Irene Flinn Professor of Medicine Chair, Department of Medicine Deputy Director, Asthma and Airway Disease
More informationJournal Club: COPD and Rehospitalization Ron Balkissoon, MD, MSc, DIH, FRCPC 1
791 Journal Club: Rehospitalization Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club: COPD and Rehospitalization Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationHow to distinguish between uncontrolled and severe asthma
How to distinguish between uncontrolled and severe asthma Watch patient using their inhaler. Discuss adherence and barriers to use Compare inhaler technique with a devicespecific checklist, and correct
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationHow to treat COPD? What is the mechanism of dyspnea? Smoking cessation
: The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationDoctor of Medicine. Alastair Stewart Dept. of Pharmacology 8 th Floor, Medical Building Rm. N802
Doctor of Medicine Alastair Stewart Dept. of Pharmacology 8 th Floor, Medical Building Rm. N802 astew@unimelb.edu.au Drugs affecting airway structure and function 2 Objectives Understand and know the mechanism
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationCOPD: Applying New Guidelines to Optimizing Evaluation and Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More information